STOCK TITAN

Tharimmune, Inc. Announces Pricing of $10 Million Public Offering

Rhea-AI Impact
(High)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Tharimmune, a clinical-stage biotechnology company (NASDAQ:THAR), announced the pricing of an underwritten public offering of 10,000,000 shares of common stock at a public offering price of $1.00 per share, resulting in gross proceeds of $10,000,000. The company intends to use the net proceeds for the advancement of TH104's phase 2 trial expected in 2024, as well as for working capital and other general corporate purposes. ThinkEquity is acting as sole book-running manager for the offering.
Positive
  • None.
Negative
  • None.

BRIDGEWATER, NJ / ACCESSWIRE / November 27, 2023 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic conditions, today announced the pricing of an underwritten public offering of 10,000,000 shares of common stock (or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof). Each share of common stock (or Pre-Funded Warrant) is being sold at a public offering price of $1.00 per share (inclusive of the Pre-Funded Warrant exercise price) for gross proceeds of $10,000,000, before deducting underwriting discounts and offering expenses. All of the shares of common stock and Pre-Funded Warrants are being offered by the Company. In addition, Tharimmune has granted the underwriters a 45-day option to purchase up to an additional 1,500,000 shares of common stock and/or Pre-Funded Warrants to cover over-allotments at the public offering price, less the underwriting discount.

The Company intends to use the net proceeds for the advancement of TH104's phase 2 trial expected in 2024, as well as for working capital and other general corporate purposes. The Company may also use a portion of the net proceeds to in-license, acquire, or invest in complementary businesses, technologies or products, however, the Company has no current commitments or obligations to do so.

The offering is expected to close on November 30, 2023, subject to satisfaction of customary closing conditions.

ThinkEquity is acting as sole book-running manager for the offering.

A registration statement on Form S-1 (File No. 333-275350) relating to the shares was filed with the Securities and Exchange Commission ("SEC") and became effective on November 27, 2023. This offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. The final prospectus will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Tharimmune, Inc.

Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in PBC, a rare and orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors. Tharimmune has a license agreement with OmniAb, Inc. to access the company's antibody discovery technology platform against specified targets. For more information please visit: www.tharimmune.com.

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the closing of the offering and the expected use of proceeds from the offering, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "depends," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "target," "should," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Factors that may cause such differences, include, but are not limited to, those discussed under Risk Factors set forth in our Annual Report on Form 10-K/A for the year ended December 31, 2022 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this release. Subsequent events and developments may cause the Company's views to change; however, the Company does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this release.

Investor Relations Contact

ir@tharimmune.com
www.tharimmune.com

SOURCE: Tharimmune, Inc.



View source version on accesswire.com:
https://www.accesswire.com/810583/tharimmune-inc-announces-pricing-of-10-million-public-offering

FAQ

What did Tharimmune announce?

Tharimmune announced the pricing of an underwritten public offering of 10,000,000 shares of common stock at a public offering price of $1.00 per share.

How much are the gross proceeds from the offering?

The gross proceeds from the offering are $10,000,000.

What are the intended uses of the net proceeds?

The company intends to use the net proceeds for the advancement of TH104's phase 2 trial expected in 2024, as well as for working capital and other general corporate purposes.

Who is the book-running manager for the offering?

ThinkEquity is acting as the sole book-running manager for the offering.

What is Tharimmune's ticker symbol?

Tharimmune's ticker symbol is THAR.

Tharimmune, Inc.

NASDAQ:THAR

THAR Rankings

THAR Latest News

THAR Stock Data

3.06M
1.91M
1.79%
1.63%
6.44%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BRIDGEWATER